LIDOFLAK 8 MG

Lidoflak is the brand name for silodosin, a selective antagonist of alpha-1 adrenoreceptors

Silodosinis a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
adrenoreceptorscan cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
affinity of silodosinto the three subtypes of the alpha-1 adrenoreceptors(alpha-1A, alpha-1B, and alpha-1D) was conducted. The results of the study demonstrated that silodosinbinds with high affinity to the alpha-1A subtype.

DOSAGE AND ADMINISTRATION
Dosing Information
once daily with a meal.
pills and capsules may carefully open the Lidoflakcapsule and sprinkle the powder inside on a tablespoonful of applesauce. The applesauce should be swallowed immediately (within 5 minutes) without chewing and followed with an 8 ozglass of cool water to ensure complete swallowing of the powder. The applesauce used should not be hot, and it should be soft enough to be swallowed without chewing. Any powder/applesauce mixture should be used immediately (within 5 minutes) and not stored for future use. Subdividing the contents of a Lidoflakcapsule is not recommended

Dosage Adjustment in Special Populations
contraindicatedin patients with severerenal impairment (CCr< 30 mL/min).
impairment (CCr30-50 mL/min), the dose should be reduced to 4 mg once daily taken with a meal.
patients with mild renal impairment(CCr50-80 mL/min)

Hepatic impairment:
with severehepatic impairment (Child-Pugh score > 10) and is therefore contraindicatedin these patients
patients with mild or moderate hepatic impairment .

Pharmacokinetic Drug-Drug Interactions
Interactions Concomitant use of ketoconazole or other strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, ritonavir) is contraindicated.
for adverse events when coadministeringLidoflak” with moderate CYP3A4 inhibitors (eg, diltiazem, erythromycin, verapamil).

Indications:
Benign Prostatic Hyperplasia
Dustal Uretar Stones